I've got the feeling that ASD has their sights set on a solid dosage form validation system for pharmacy use which will also test liquids. I believe they even make mention of it.
I can't see why they would want to license CDEX to test solids and create a competitor. Not that there would be competition since RxSpec tests nondestructively whilst (TM- DDMan) Valimed tests destructively.
Nope. CDEX is in their little niche market of high-risk, compounded IV medications and that's where they're going to stay as long as ASD allows it IMO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.